Evidence map›Paper›PMID 42662279›Full record

ArticleFrontiers in medicine2026

Metabolic syndrome is independently associated with 1-year readmission in patients with alcohol-associated cirrhosis.

Jiarui Zheng, Yuxuan Song, Yanxu Hao, Bo Feng, Yandi Xie

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiarui ZhengPeking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing, China.
Yuxuan SongPeking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing, China.
Yanxu HaoBeijing Jingmei Group General Hospital, Beijing, China.
Bo FengPeking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing, China.
Yandi XiePeking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aimed to investigate the relationship between metabolic syndrome (MetS) and the risk of 1-year readmission in patients with alcohol-associated cirrhosis and to identify the independent predictors of this outcome. Methods: This retrospective cohort study included 379 patients with alcohol-associated cirrhosis who were hospitalized between January 2012 and December 2023. Patients were categorized into two groups according to the presence or absence of MetS. Baseline characteristics, liver function indicators, complications, and causes of readmission were compared. A multivariable logistic regression analysis was used to identify independent predictors of 1-year readmission. Stratified analyses were conducted to evaluate potential effect modification. Results: Of the 379 patients (98.9% were male patients, mean age 54.1 ± 10.1 years), 40 of them (10.6%) had MetS. Patients with MetS had a significantly higher 1-year readmission rate than those without MetS (65.0% vs. 44.5%, Conclusion: Metabolic syndrome is an independent predictor of 1-year readmission in patients with alcohol-associated cirrhosis, influencing the risk of readmission together with factors such as hepatic encephalopathy and variceal bleeding. The interplay between metabolic dysfunction and alcohol-associated cirrhosis warrants further investigation, and our findings underscore the importance of metabolic risk management in this population.

Indexed as

alcohol-associated cirrhosismetabolic dysfunction and alcohol-associated liver diseasemetabolic dysfunction-associated steatotic liver diseasemetabolic syndromereadmission

Identifiers

PMID42662279
PMCPMC13519395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.